Interactions between viral RNA and the integrase enzyme are required for HIV-1 particles to become infectious, a process that can be disrupted through multiple mechanisms.
Virus particles rely on host cells to replicate and infect other cells. Key steps in this process include entry into the host cell, gene expression, and the production of new viral particles. For some viruses, including HIV-1, this last step starts with the assembly of immature, non-infectious virus particles; the complex process by which these particles mature is not fully understood.
Successful HIV-1 maturation culminates in the assembly of a conical-shaped core structure called the capsid, which encloses the viral RNA (vRNA) as well as two viral enzymes: reverse transcriptase, which produces DNA from vRNA, and integrase, which is best known for catalyzing the integration of vDNA into the genome of the host. It was shown many years ago that some deletions in the gene that codes for integrase result in a curious, eccentric core phenotype: empty capsids are formed and an electron-dense material, which is presumed to contain the vRNA, is present outside of the capsid (Engelman et al., 1995; Figure 1). This phenotype is associated with defects in multiple steps of the virus replication cycle, including reverse transcription.
Following this discovery, numerous integrase mutants – known as class II mutants – were shown to display a similar wide-ranging phenotype (Jurado et al., 2013; Quillent et al., 1996). Multiple studies have suggested that these class II mutants have defects in reverse transcription, possibly because they have lost their vRNA, or because reverse transcriptase becomes physically separated from the genetic information upon infection of a target cell (Koneru et al., 2019; Madison et al., 2017). Now, in eLife, Sebla Kutluay of Washington University in St. Louis and colleagues – including Jennifer Elliot as first author – report how class II integrase substitutions impair the maturation of HIV-1 particles (Elliott et al., 2020).
First, Elliott et al. confirmed a previous observation: that the binding of integrase to vRNA may underpin its role during HIV-1 maturation (Kessl et al., 2016). The team examined replication defects induced by a panel of more than 25 class II integrase substitutions and, as expected, particle infectivity and reverse transcription products dropped in all mutants. Moreover, the class II substitutions disrupted the interactions between integrase and vRNA in three distinct ways.
For one subset of substitutions, the levels of integrase in both cells and virus particles were significantly decreased, suggesting that these mutations prevent the expression of integrase or its packaging inside new virus particles. The other two subsets involved the disruption of integrase binding to vRNA, rather than the packaging of the enzyme into the particles. Interestingly, many substitutions involve integrase residues outside the region previously implicated in RNA binding (Kessl et al., 2016). The second subset of mutations resulted in the interaction between the enzyme and vRNA being directly blocked, while the third subset led to interactions between integrase enzymes being impaired. In particular, fewer enzymes were able to form tetramers, the structures containing four copies of integrase that normally bind to vRNA.
Finally, Elliott et al. confirmed that the eccentric core phenotype was present in each of the mutants, and they observed lower amounts of vRNA in target cells just after infection. This suggests that without the protection of the capsid shell, exposure to the intracellular environment decreases the stability of the vRNA.
The recent discovery of a new class of HIV-1 inhibitors, known as ALLINIs (allosteric integrase inhibitors), is making these results particularly relevant (reviewed in Elliott and Kutluay, 2020; Engelman, 2019; Kleinpeter and Freed, 2020). These compounds induce aberrant integrase multimerization and therefore disrupt the binding of the enzyme to vRNA, resulting in particles with eccentric cores reminiscent of those found in class II mutants. Further characterization of these mutants, and of the role of integrase during HIV-1 maturation, may help in the development of ALLINIs as potential HIV-1 therapeutics.
This work also raises several questions. First, it is still unclear whether the integrase only helps the vRNA to be packaged into the capsid, or if it also participates in the construction of the capsid itself. While Elliott et al. show that capsids assembled in particles with mutant integrase are as stable as those assembled with the normal version of the enzyme, it was previously reported that ALLINIs and a class II integrase mutation disrupt the formation of the capsid (Fontana et al., 2015). Second, what happens to integrase when ‘empty’ capsids are assembled? The experiments by Elliott et al. reveal that mutant integrase enzymes, while physically associated with the capsid, are rapidly degraded after infection – potentially because they are located, unprotected, on the outside of the capsid. This suggests that in the absence of an interaction between integrase and vRNA, neither the enzyme nor the genetic material is packaged into the capsid, raising further questions about the molecular mechanisms driving packaging. Next, the fact that ALLINIs act by inducing aberrant integrase multimerization suggests that other classes of small molecules could be developed, which interfere with the packaging of vRNA into the capsid through different mechanisms. Finally, it remains unclear whether integrase enzymes in viruses related to HIV-1 also promote vRNA packaging into the capsid during maturation. Answering these questions will allow a greater understanding of how HIV-1 and related viruses mature, with implications for basic biology and new drug development.
Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibitionJournal of Biological Chemistry 294:15137–15157.https://doi.org/10.1074/jbc.REV119.006901
- Version of Record published: November 17, 2020 (version 1)
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Downloads (link to download the article as PDF)
Download citations (links to download the citations from this article in formats compatible with various reference manager tools)
Open citations (links to open the citations from this article in various online reference manager services)
The production of reactive oxygen species (ROS) is a ubiquitous defense response in plants. Adapted pathogens evolved mechanisms to counteract the deleterious effects of host-derived ROS and promote infection. How plant pathogens regulate this elaborate response against ROS burst remains unclear. Using the rice blast fungus Magnaporthe oryzae, we uncovered a self-balancing circuit controlling response to ROS in planta and virulence. During infection, ROS induces phosphorylation of the high osmolarity glycerol pathway kinase MoOsm1 and its nuclear translocation. There, MoOsm1 phosphorylates transcription factor MoAtf1 and dissociates MoAtf1-MoTup1 complex. This releases MoTup1-mediated transcriptional repression on oxidoreduction-pathway genes and activates the transcription of MoPtp1/2 protein phosphatases. In turn, MoPtp1/2 dephosphorylate MoOsm1, restoring the circuit to its initial state. Balanced interactions among proteins centered on MoOsm1 provide a means to counter host-derived ROS. Our findings thereby reveal new insights into how M. oryzae utilizes a phosphor-regulatory circuitry to face plant immunity during infection.
Many photosynthetic organisms employ a CO2 concentrating mechanism (CCM) to increase the rate of CO2 fixation via the Calvin cycle. CCMs catalyze ≈50% of global photosynthesis, yet it remains unclear which genes and proteins are required to produce this complex adaptation. We describe the construction of a functional CCM in a non-native host, achieved by expressing genes from an autotrophic bacterium in an Escherichia coli strain engineered to depend on rubisco carboxylation for growth. Expression of 20 CCM genes enabled E. coli to grow by fixing CO2 from ambient air into biomass, with growth in ambient air depending on the components of the CCM. Bacterial CCMs are therefore genetically compact and readily transplanted, rationalizing their presence in diverse bacteria. Reconstitution enabled genetic experiments refining our understanding of the CCM, thereby laying the groundwork for deeper study and engineering of the cell biology supporting CO2 assimilation in diverse organisms.